Yüklüyor......
Laboratory monitoring of hemophilia A treatments: new challenges
Monitoring factor VIII (FVIII) activity has traditionally been complicated by discrepancies between assays for the various sorts of FVIII molecules. The advent of novel nonfactor therapies (emicizumab, fitusiran, and anti-tissue factor pathway inhibitor antibodies) in hemophilia A poses a new level...
Kaydedildi:
| Yayımlandı: | Blood Adv |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7218434/ https://ncbi.nlm.nih.gov/pubmed/32396619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000849 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|